Collar Amanda L, Linville Alexandria C, Core Susan B, Frietze Kathryn M
Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Clinical and Translational Science Center, University of New Mexico Health Sciences, Albuquerque, NM 87131, USA.
Vaccines (Basel). 2022 May 30;10(6):875. doi: 10.3390/vaccines10060875.
(Ct) is the most common bacterial sexual transmitted pathogen, yet a vaccine is not currently available. Here, we used the immunogenic bacteriophage MS2 virus-like particle (VLP) technology to engineer vaccines against the Ct major outer membrane protein variable domain 4 (MOMP-VD4), which contains a conserved neutralizing epitope (TTLNPTIAG). A previously described monoclonal antibody to the MOMP-VD4 (E4 mAb) is capable of neutralizing all urogenital Ct serovars and binds this core epitope, as well as several non-contiguous amino acids. This suggests that this core epitope may require conformational context in order to elicit neutralizing antibodies to Ct. In order to identify immunogens that could elicit neutralizing antibodies to the TTLNPTIAG epitope, we used two approaches. First, we used affinity selection with a bacteriophage MS2-VLP library displaying random peptides in a constrained, surface-exposed loop to identify potential E4 mAb mimotopes. After four rounds of affinity selection, we identified a VLP-displayed peptide (HMVGSTKWTN) that could bind to the E4 mAb and elicited serum IgG that bound weakly to Ct elementary bodies by ELISA. Second, two versions of the core conserved TTLNPTIAG epitope (TTLNPTIAG and TTLNPTIAGA) were recombinantly expressed on the coat protein of the MS2 VLP in a constrained, surface-exposed loop. Mouse immune sera IgG bound to Ct elementary bodies by ELISA. Immunization with these MS2 VLPs provided protection from vaginal infection in a murine challenge model. These data suggest that short peptide epitopes targeting the MOMP-VD4 could be appropriate for Ct vaccine design when displayed on an immunogenic bacteriophage VLP vaccine platform.
沙眼衣原体(Ct)是最常见的细菌性性传播病原体,但目前尚无可用疫苗。在此,我们利用免疫原性噬菌体MS2病毒样颗粒(VLP)技术设计针对Ct主要外膜蛋白可变区4(MOMP - VD4)的疫苗,该区域包含一个保守的中和表位(TTLNPTIAG)。一种先前描述的针对MOMP - VD4的单克隆抗体(E4 mAb)能够中和所有泌尿生殖道Ct血清型,并结合该核心表位以及几个不连续的氨基酸。这表明该核心表位可能需要构象背景才能引发针对Ct的中和抗体。为了鉴定能够引发针对TTLNPTIAG表位的中和抗体的免疫原,我们采用了两种方法。首先,我们使用噬菌体MS2 - VLP文库进行亲和选择,该文库在一个受限的、表面暴露的环中展示随机肽,以鉴定潜在的E4 mAb模拟表位。经过四轮亲和选择,我们鉴定出一种VLP展示的肽(HMVGSTKWTN),它能够与E4 mAb结合,并通过ELISA引发与Ct原体微弱结合的血清IgG。其次,核心保守的TTLNPTIAG表位的两个版本(TTLNPTIAG和TTLNPTIAGA)在MS2 VLP的外壳蛋白上以受限的、表面暴露的环的形式进行重组表达。小鼠免疫血清IgG通过ELISA与Ct原体结合。用这些MS2 VLP进行免疫在小鼠攻击模型中提供了对阴道感染的保护。这些数据表明,当在免疫原性噬菌体VLP疫苗平台上展示时,靶向MOMP - VD4的短肽表位可能适用于Ct疫苗设计。